117 related articles for article (PubMed ID: 20975258)
1. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
[TBL] [Abstract][Full Text] [Related]
2. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
3. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
4. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Winn SK; Ellis S; Savage P; Sampson S; Marsh JE
Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026
[TBL] [Abstract][Full Text] [Related]
5. Lethal acute liver failure in a patient treated with sunitinib.
Guillen SS; Meijer M; de Jongh FE
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26933184
[TBL] [Abstract][Full Text] [Related]
6. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
7. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
Khakoo AY; Kassiotis CM; Tannir N; Plana JC; Halushka M; Bickford C; Trent J; Champion JC; Durand JB; Lenihan DJ
Cancer; 2008 Jun; 112(11):2500-8. PubMed ID: 18386829
[TBL] [Abstract][Full Text] [Related]
8. Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.
Wu CF; Chuang WP; Li AH; Hsiao CH
J Chin Med Assoc; 2009 Jun; 72(6):323-7. PubMed ID: 19541568
[TBL] [Abstract][Full Text] [Related]
9. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
[No Abstract] [Full Text] [Related]
10. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
11. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Di Lorenzo G; Autorino R; Bruni G; Cartenì G; Ricevuto E; Tudini M; Ficorella C; Romano C; Aieta M; Giordano A; Giuliano M; Gonnella A; De Nunzio C; Rizzo M; Montesarchio V; Ewer M; De Placido S
Ann Oncol; 2009 Sep; 20(9):1535-1542. PubMed ID: 19474115
[TBL] [Abstract][Full Text] [Related]
14. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
17. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
Telli ML; Witteles RM; Fisher GA; Srinivas S
Ann Oncol; 2008 Sep; 19(9):1613-8. PubMed ID: 18436521
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis.
Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R
Cancer; 2012 Jun; 118(12):3165-72. PubMed ID: 21956360
[TBL] [Abstract][Full Text] [Related]
20. Guillain-Barré syndrome after treatment with sunitinib malate?
Mulherin B; Loconte NK; Holen KD
Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
